doi: 10.1016/j.leukres.2004.07.005.
Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor
Affiliations
- PMID: 15661266
- DOI: 10.1016/j.leukres.2004.07.005
Item in Clipboard
Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor
Leuk Res.
2005 Mar.
Abstract
We directed the human natural killer (NK) cell line YT by gene transfer of a humanized chimeric immunoglobulin T cell receptor to CD33, a marker on myeloid leukemias. The chimeric receptor was generated using a CD33 specific single-chain Fv (scFv) fragment based on the humanized antibody HuM195, the human IgG1 Fc domains and the human CD3 zeta signal chain. YT cells transfected by electroporation with the chimeric receptor gene specifically lysed the acute myeloid leukemia (AML) cell line KG1. This gene-modified NK cell line available in unlimited source could be an attractive tool in immunotherapy.
Similar articles
-
Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.Cancer Gene Ther. 2002 Apr;9(4):390-8. doi: 10.1038/sj.cgt.7700453. Cancer Gene Ther. 2002. PMID: 11960290
-
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.Br J Haematol. 2010 Sep;150(5):574-86. doi: 10.1111/j.1365-2141.2010.08300.x. Epub 2010 Jul 16. Br J Haematol. 2010. PMID: 20636437
-
Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.Cancer Gene Ther. 2004 Apr;11(4):297-306. doi: 10.1038/sj.cgt.7700685. Cancer Gene Ther. 2004. PMID: 15002034
-
Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.Anticancer Res. 2005 Nov-Dec;25(6A):3725-32. Anticancer Res. 2005. PMID: 16302732 Review.
-
Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future.Nat Rev Immunol. 2004 Mar;4(3):190-8. doi: 10.1038/nri1306. Nat Rev Immunol. 2004. PMID: 15039756 Review. No abstract available.
Cited by
-
CAR-NK cells for cancer immunotherapy: from bench to bedside.Biomark Res. 2022 Mar 18;10(1):12. doi: 10.1186/s40364-022-00364-6. Biomark Res. 2022. PMID: 35303962 Free PMC article. Review.
-
High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells.BMC Biotechnol. 2013 Jun 26;13:52. doi: 10.1186/1472-6750-13-52. BMC Biotechnol. 2013. PMID: 23802841 Free PMC article.
-
Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines.BMC Med Genomics. 2019 Mar 13;12(Suppl 2):44. doi: 10.1186/s12920-019-0489-4. BMC Med Genomics. 2019. PMID: 30871576 Free PMC article.
-
Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.Mol Ther. 2017 Dec 6;25(12):2607-2619. doi: 10.1016/j.ymthe.2017.08.010. Epub 2017 Aug 19. Mol Ther. 2017. PMID: 28919377 Free PMC article.
-
Stem cell-derived CAR T cells traffic to HIV reservoirs in macaques.JCI Insight. 2021 Jan 11;6(1):e141502. doi: 10.1172/jci.insight.141502. JCI Insight. 2021. PMID: 33427210 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
